[12] Patent
[11] Patent No.:GC0009494  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/142565
Date of the Decision to Grant the Patent:31/Dec/2018

[21] Application No.:GC 2014-26712

[22] Filing Date:13/3/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.

[72] Inventors:1- Robert AVERSA،2- Paul A. BARSANTI،3- Matthew BURGER،4- Michael Patrick DILLON،5- Alan DIPESA،6- Cheng HU،7- Yan LOU،8- Gisele NISHIGUCHI،9- Yue PAN،10- Valery POLYAKOV،11- Savithri RAMURTHY،12- Alice RICO،13- Lina SETTI،14- Aaron SMITH،15- Sharadha SUBRAMANIAN،16- Benjamin TAFT،17- Huw TANNER،18- Lifeng WAN،19- Naeem YUSUFF

[73] Owner: Novartis AG, Lichtstrasse 35 4056, Basel , Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office




Int. Cl.: C07D 213/74, 213/75, 233/88, 237/20, 239/42, 241/20, 401/04, 401/12, 401/14, 403/04, 403/12, 405/04, 405/12, 405/14, 413/14 (2006.01)

[56] Cited Documents:

-WO 2006005918 A1 (ASTRAZENECA AB [SE]) 19 January 2006  
Examiner: PH. Mohammad S. AlMousa

[57] Abstract: The present invention provides compounds of Formula (I) (I)as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
No. of claims: 24


Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.